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Abstract
Background:  It is well established that ACE-inhibitors should be avoided in patients with renal
artery stenosis. In recent years it has also been recommended that caution should be demonstrated
when angiotensin II blockers are used in the same type of patients but the evidence is based only
on few cases.
Results:  We describe a case where use of the angiotensin II antagonist candesartan (Atacand)
induced renal failure in a patient with bilateral renal artery stenosis. The course of the case is
enlighted  by  results  from  sequential  renography,  selective  renal  vein  catheterisation  for
measurement of renin, and angiographic findings.
Conclusions:  In patients with renal artery stenosis the angiotensin II antagonist candesartan
should be avoided.
Background
ACE-inhibitors are well-established in treatment of hy-
pertension. In recent years selective angiotensin II AT1-
receptor antagonists have been introduced as an alterna-
tive. Although the same system is manipulated, the two
types of medication differ in several ways. In brief, the
major differences are: 1) whereas blockade of angi-
otensin II formation by ACE-inhibition is incomplete
due to alternative synthesis pathways, e.g. chymase
pathway, angiotensin II antagonists block the receptors
at the target organ, 2) the relative effect on AT1- and AT2-
receptors, and 3) differential effect on bradykinin metab-
olism since ACE inhibition inhibits ACE inactivation of
bradykinin. The latter is thought to be the major reason
for the higher rate of side-effects seen with ACE inhibi-
tors compared to angiotensin II antagonists. Whereas
the evidence that ACE-inhibitors should be avoided in
patients with renal artery stenosis is substantial, the evi-
dence is more sparse with regard to angiotensin II antag-
onists and restricted to losartan.
Below, we present a case of reversible deterioration in re-
nal function following treatment with the angiotensin II
antagonist candesartan.
Case
A 60 years old male with previous alcohol abuse and
known hypertension for the last 5 years was admitted to
our hospital with a diagnosis of hypertension. At the time
of admission the blood pressure (BP) was 230/140
mmHg despite treatment with metoprolol (Selozok),
amiloride/hydrochlorthiazide (Sparkal Mite) and cande-
sartan (Atacand). The patient was hyperkalemic and had
an increased serum-creatinine (237 µ mol/l). Antihyper-
tensive treatment was intensified including addition of
loop-diuretic and hydration.
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Following normalization of BP, serum-potassium and
serum-creatinine the patient was discharged with an ap-
pointment for ambulatory renography. 99mTc-DTPA re-
nography (Fig. 1), performed after the patient had been
on candesartan treatment for 4 months, showed sym-
metrical renal function, however, the absolute renal
function was almost abolished (total estimated GFR 4
ml/min).
At the time the patient had an elevated serum-creatinine
(817 µ mol/l) and urea (48 mmol/l) and was anuric. Diu-
resis was re-established following use of intravenous
loop-diuretic and hydration. Renal biochemistry then
improved. Atacand was discontinued and 3 weeks later
renography (Fig. 2) demonstrated improved renal func-
tion: total estimated GFR 47 ml/min. The left kidney was
responsible for only 1/3 of the total renal function.
Later, a selective catheterisation of the renal veins was
performed for measurement of renin. The renin meas-
urements showed increased left sided renin production
(Table 1). Arteriography showed an arteriosclerotic ab-
dominal aorta with significant bilateral stenosis of the
renal arteries, more prominent on the left side.
The patient was referred to PTA of the left renal artery
stenosis. Under the procedure for PTA, which was un-
successful bilateral renal occlusion occurred. The patient
then underwent bilateral vein graft renal arterial by-
passes.
Two months after this operation renography showed im-
proved absolute and relative function of the left kidney
whereas the absolute function of the right kidney was un-
changed (Fig. 3). Furthermore, pre- and post-captopril
renography appearances were similar (Figs. 3-4), indi-
cating no functionally important stenosis. A 24-hour am-
bulatory BP measurement showed well-regulated BP
under treatment with amlodipine (Norvasc), doxazosin
(Carduran) and bendroflumethiazide (Centyl).
Discussion
It is well established that ACE inhibitors should be avoid-
ed in patients with critical renal artery stenosis. In con-
trast, this is not as well established with respect to
angiotensin II antagonists. Over the last years a few cases
have shown that renal function may be impaired if the
angiotensin II antagonist losartan is used in patients
with renal artery stenosis [1,2,3,4] but two of these cases
were in the special situation of kidney transplants [3,4].
To our knowledge we are the first to report a case of renal
Figure 1
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impairment induced by the angiotensin II antagonist
candesartan. Subsequent to the introduction of losartan,
several other angiotensin II blockers have been market-
ed over the last couple of years and differences in recep-
tor affinity and kinetics are reported. Therefore, our case
supports the thought that caution should be shown using
other types of angiotensin II antagonists. As mentioned
in the introduction several differences exist between
ACE inhibitors and angiotensin II, AT1-receptor antago-
nists. Therefore, differences with regard to interference
with renal function and thereby when the compound
should be avoided could exist. From a theoretical point of
view however, one would expect that both principles of
blockade should be avoided in renal artery stenosis. The
mechanism of the renin-angiotensin system in regula-
tion of renal function is believed primarily to be due to
the effect of angiotensin II on the efferent arteriolar tone
keeping the pressure relatively constant in the glomeru-
lus and thereby keeping GFR constant over a wide range
of perfusion pressures, i.e. systemic BP. However, the
differential effect on e.g. bradykinin, which is a vasodila-
tor and also have other actions, could in theory make the
two types of blockade clinically different. At present, the
relative risk of precipitating renal failure by using the dif-
ferent compounds is unsettled. Thus in one case renal
function deteriorated following both the ACE inhibitor
enalapril and losartan [1]. In contrast, another case-re-
port observed deterioration of renal function during
enalapril treatment but no effect of subsequent losartan
treatment [5]. Conversely, in a study comparing the use-
fulness of the ACE inhibitor captopril and losartan re-
nography for detection of renovascular hypertension it
was in a single case found that losartan but not captopril
induced a fall in renal function in a kidney with more
than 80% renal artery stenosis [6].
Our case also demonstrates that renography is an easy
way to examine and follow patients with deterioration of
renal function during treatment with angiotensin II an-
tagonists or ACE inhibitors. When of relevance, the addi-
tional use of angiography and selective renin
measurements add further evidence for the reason for
renal impairment.
We conclude, that further studies are needed to demon-
strate potential differences in the use of ACE inhibitors
and angiotensin II antagonists in patients with suspected
renal artery stenosis. Until then, both compounds should
be avoided in this category of patients.
Figure 2
Renography 3 weeks after discontinuation of candesartan treatment.BMC Nephrology (2001) 2:1 http://www.biomedcentral.com/1471-2369/2/1
Figure 3
Renography following bilateral renal by-pass surgery.
Table 1: Levels of renin in the renal veins demonstrating increased levels on the left side. Values are in mIU/l.
Right renal vein Left renal vein Reference (antecubital vein)
Without loop-diuretic 92 148 92
stimulation
With loop-diuretic 105 230 103
stimulationBMC Nephrology (2001) 2:1 http://www.biomedcentral.com/1471-2369/2/1
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